Clinical trials are needed to confirm safety and dosing
Preclinical evidence suggests BPC-157 may enhance recovery from muscle, tendon, ligament, and bone injuries by promoting angiogenesis, cell growth, and reducing inflammation.[4] Whats the best form oral, sublingual, topical, or injectable
roughly 50-98 % of an administered dose is renally excreted unmetabolized, underscoring the low intrinsic toxicity
Published work on intranasal peptide delivery (for insulin analogs, calcitonin, and oxytocin) demonstrates that bioavailability for this size class without enhancers is typically in the low single-digit percent range, though these data are from different peptides with different charge profiles
In addition, CMS is amenable to meeting with applicants or potential applicants to facilitate information sharing to support the evaluation of an OPPS device pass-through payment application or discuss general application criteria, including the substantial clinical improvement criterion
S., Nyman, E